Salutaris Medical Devices

Executive Summary

Salutaris Medical Devices is a privately held medical device company based in Tucson, Arizona, focused on transforming the treatment landscape for age-related macular degeneration (AMD) and other challenging retinal diseases. Founded in 2014, the company aims to provide an affordable, accessible, one-time treatment that can last a lifetime, addressing significant unmet needs in ophthalmology. Unlike current standard-of-care therapies that require frequent intravitreal injections, Salutaris' approach seeks to reduce treatment burden and improve patient compliance, potentially expanding access to underserved populations globally. The company is currently in Phase 1 development, indicating its technology is at an early but promising stage of clinical evaluation. Salutaris' technology leverages a unique drug delivery platform designed to achieve sustained therapeutic effect with a single administration. While specific details of the device and its payload remain proprietary, the potential to disrupt the multi-billion-dollar retinal disease market is substantial. The company operates in a competitive landscape dominated by established players, yet its value proposition of a one-time, lifetime treatment differentiates it. Success in Phase 1 trials and subsequent clinical milestones could position Salutaris as a leader in retinal therapeutics. However, the early-stage nature and lack of disclosed funding or valuation data introduce significant risk. The upcoming catalysts will be critical in validating the platform's safety and efficacy, and in attracting the capital needed for further development.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 Safety and Tolerability Data Readout40% success
• Q2 2027Series A or B Financing Round60% success
• Q4 2026FDA Pre-IND or IDE Meeting Outcome70% success